NCT00285428 - Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

hA20-humanized anti-CD20 antibody

once weekly iv dosing for 4 weeks

Trial Locations (3)

New York Presbyterian Hospital/Cornell Medical Center, New York

University Hospital of Pennsylvania, Philadelphia

MD Anderson Cancer Center, Houston